<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34271264</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-6265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>50</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current opinion in virology</Title>
          <ISOAbbreviation>Curr Opin Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <EndPage>22</EndPage>
          <MedlinePgn>17-22</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coviro.2021.06.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1879-6257(21)00066-3</ELocationID>
        <Abstract>
          <AbstractText>Despite the availability of vaccines, there remains an urgent need for antiviral drugs with potent activity against SARS-CoV-2, the cause of COVID-19. Millions of people are immune-suppressed and may not be able to mount a fully protective immune response after vaccination. There is also an increasingly critical need for a drug to cover emerging SARS-CoV-2 variants, against which existing vaccines may be less effective. Here, we describe the evolution of molnupiravir (EIDD-2801, MK-4482), a broad-spectrum antiviral agent originally designed for the treatment of Alphavirus infections, into a potential drug for the prevention and treatment of COVID-19. When the pandemic began, molnupiravir was in pre-clinical development for the treatment of seasonal influenza. As COVID-19 spread, the timeline for the development program was moved forward significantly, and focus shifted to treatment of coronavirus infections. Real time consultation with regulatory authorities aided in making the acceleration of the program possible.</AbstractText>
          <CopyrightInformation>Copyright Â© 2021 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>George R</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA; Drug Innovation Ventures at Emory (DRIVE), Atlanta, GA, USA; Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: George.r.painter@emory.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Natchus</LastName>
            <ForeName>Michael G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>Oren</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds LS2 9LH, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holman</LastName>
            <ForeName>Wendy</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>Wendy P</ForeName>
            <Initials>WP</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>75N93019C00058</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HHSN272201500008C</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Opin Virol</MedlineTA>
        <NlmUniqueID>101560941</NlmUniqueID>
        <ISSNLinking>1879-6257</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>20</Hour>
          <Minute>21</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34271264</ArticleId>
        <ArticleId IdType="pmc">PMC8277160</ArticleId>
        <ArticleId IdType="doi">10.1016/j.coviro.2021.06.003</ArticleId>
        <ArticleId IdType="pii">S1879-6257(21)00066-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054â1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7270627</ArticleId>
            <ArticleId IdType="pubmed">32171076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y., et al.  A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265â269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7094943</ArticleId>
            <ArticleId IdType="pubmed">32015508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lescure F.-X., Bouadma L., Nguyen D., Parisey M., Wicky P.-H., Behillil S., Gaymard A., Bouscambert-Duchamp M., Donati F., Le Hingrat Q., et al.  Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20:697â706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7156120</ArticleId>
            <ArticleId IdType="pubmed">32224310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497â506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang J., Xing F., Liu J., Yip C.C.-Y., Poon R.W.-S., et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514â523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7159286</ArticleId>
            <ArticleId IdType="pubmed">31986261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., Liu H., Madden V.J., Krzystek H.M., De C., et al.  SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451â457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6:11â18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Hart M., Natchus M.G., Painter G.R., Plemper R.K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020;218:16â28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., SchÃ¤fer A., Dinnon K.H., Stevens L.J., et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., et al.  Small-molecule antiviral Î²-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348â01319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.-J., Toots M., Lee S., Lee M.-E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., et al.  Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele K.E., Twenhafel N.A. REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol. 2010;47:790â805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20551475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reichert E., Clase A., Bacetty A., Larsen J. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur Bioterror. 2009;7:413â427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zacks M.A., Paessler S. Encephalitic alphaviruses. Vet Microbiol. 2010;140:281â286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2814892</ArticleId>
            <ArticleId IdType="pubmed">19775836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele K., Reed D.S., Glass P.J., Hart M.K., Ludwig G.V., Pratt W.D., Parker M.D., Smith J.F.  In: Textbooks of Military MedicineâMedical Aspects of Biological Warfare. Dembek Z.F., editor. Borden Institute; Washington, DC, Office of the Surgeon General, Falls Church, VA: 2007. Alphavirus encephalitides; pp. 241â270.</Citation>
        </Reference>
        <Reference>
          <Citation>Giry C., Roquebert B., Li-Pat-Yuen G., Gasque P., Jaffar-Bandjee M.C. Improved detection of genus-specific Alphavirus using a generic TaqManÂ® assay. BMC Microbiol. 2017;17:164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5525299</ArticleId>
            <ArticleId IdType="pubmed">28738838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forrester N.L., Wertheim J.O., Dugan V.G., Auguste A.J., Lin D., Adams A.P., Chen R., Gorchakov R., Leal G., Estrada-Franco J.G., et al.  Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas. PLoS Negl Trop Dis. 2017;11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5557581</ArticleId>
            <ArticleId IdType="pubmed">28771475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel P., Abplanalp D., Kell W., Ibrahim M.S., Downs M.B., Pratt W.D., Davis K.J. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch Pathol Lab Med. 1996;120:164â172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8712896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryzhikov A.B., Ryabchikova E.I., Sergeev A.N., Tkacheva N.V. Spread of Venezuelan equine encephalitis virus in mice olfactory tract. Arch Virol. 1995;140:2243â2254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8572944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolhouse M.E., Brierley L., McCaffery C., Lycett S. Assessing the epidemic potential of RNA and DNA viruses. Emerg Infect Dis. 2016;22:2037â2044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5189130</ArticleId>
            <ArticleId IdType="pubmed">27869592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woolhouse M.E.J., Brierley L. Epidemiological characteristics of human-infective RNA viruses. Sci Data. 2018;5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5819479</ArticleId>
            <ArticleId IdType="pubmed">29461515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu B., Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016;113:E4005âE4014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4948327</ArticleId>
            <ArticleId IdType="pubmed">27339134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorbalenya A.E., Pringle F.M., Zeddam J.L., Luke B.T., Cameron C.E., Kalmakoff J., Hanzlik T.N., Gordon K.H., Ward V.K. The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J Mol Biol. 2002;324:47â62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7127740</ArticleId>
            <ArticleId IdType="pubmed">12421558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ollis D.L., Brick P., Hamlin R., Xuong N.G., Steitz T.A. Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP. Nature. 1985;313:762â766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3883192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Clercq E., Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695â747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978613</ArticleId>
            <ArticleId IdType="pubmed">27281742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordheim L.P., Durantel D., Zoulim F., Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447â464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23722347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890544</ArticleId>
            <ArticleId IdType="pubmed">29562753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehteshami M., Tao S., Zandi K., Hsiao H.M., Jiang Y., Hammond E., Amblard F., Russell O.O., Merits A., Schinazi R.F. Characterization of Î²-d-N(4)-hydroxycytidine as a novel inhibitor of chikungunya virus. Antimicrob Agents Chemother. 2017;61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5365705</ArticleId>
            <ArticleId IdType="pubmed">28137799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O., Nguyen X.N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses. 2015;7:6233â6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costantini V.P., Whitaker T., Barclay L., Lee D., McBrayer T.R., Schinazi R.F., VinjÃ© J. Antiviral activity of nucleoside analogues against norovirus. Antivir Ther. 2012;17:981â991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7751060</ArticleId>
            <ArticleId IdType="pubmed">22910194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyrc K., Bosch B.J., Berkhout B., Jebbink M.F., Dijkman R., Rottier P., van der Hoek L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006;50:2000â2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1479111</ArticleId>
            <ArticleId IdType="pubmed">16723558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivanov M.A., Antonova Ã, Maksimov A.V., Pigusova L.K., Belanov E.F., Aleksandrova L.A. New N4-hydroxycytidine derivatives: synthesis and antiviral activity. Collect Czechoslov Chem Commun. 2006;71:1099â1106.</Citation>
        </Reference>
        <Reference>
          <Citation>Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., Sidwell R.W. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir Chem Chemother. 2004;15:15â22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15074711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuyver L.J., Whitaker T., McBrayer T.R., Hernandez-Santiago B.I., Lostia S., Tharnish P.M., Ramesh M., Chu C.K., Jordan R., Shi J., et al.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother. 2003;47:244â254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC149013</ArticleId>
            <ArticleId IdType="pubmed">12499198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Bowen R.A., Bluemling G.R., DeBergh J., Edpuganti V., Gruddanti P.R., Guthrie D.B., Hager M., Kuiper D.L., Lockwood M.A., et al.  The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019;171</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31494195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nesslany F. The current limitations of in vitro genotoxicity testing and their relevance to the in vivo situation. Food Chem Toxicol. 2017;106:609â615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27591928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeller A., Pfuhler S., Albertini S., Bringezu F., Czich A., Dietz Y., Fautz R., Hewitt N.J., Kirst A., Kasper P. A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens. Mutagenesis. 2018;33:179â193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29669112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65:e02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
